Synthesis and Antitumor Activity of Novel Pyrimidine Monocyclic Nonclassical Antifolates

Jing Cong,Fang,Liangmin Xue,Meng Wang,Chao Tian,Xiaowei Wang,Junyi Liu,Zhili Zhang
DOI: https://doi.org/10.6023/cjoc202007006
2021-01-01
Chinese Journal of Organic Chemistry
Abstract:Regarding the nonclassical antifolates 6-(4'-methylphenethyl)-5-chloroacetyl-5,6,7,8-tetrahydropyrido[3,2-d]pyrimidine (wm-8.2) as the lead compound, in order to improve molecular flexibility and simplify molecular structure, two series of compounds were designed and synthesized according to the 6-H and 6-methyl group. And the effects of carbon chain length and aromatic heterocyclic side chain on antitumor activity were investgated. Besides, the activities of key intermediates with molecular skeleton of folic acid inhibitor were measured to study the effect of the chloroacetyl group at N(5) position. Structures of 36 target compounds and key intermediates were confirmed by H-1 NMR, C-13 NMR and MS. The biological activity results showed that 6-methyl-2,4-diamino-5-(N-(4-methylphenyl)propyl-N-(2-chloroacetyl))aminopyrimidine (6b-3), which had three-carbon bridge and p-methylbenzene ring side chain, exhibited the best inhibition activities against HL-60, A549 and HCT116 cells with IC50 values as 0.25, 0.83 and 0.63 mu mol.L-1 respectively. 6-Methyl-2,4-diamino-5-(N-(4-methylphenyl)propyl)aminopyrimidine (5b-3), the key intermediate of 6b-3, showed excellent dihydrofolate reductase inhibitory activity. Molecular docking studies further explored the structure-activity relationship and possible causes of the difference inhibitory activity against dihydrofolate reductase.
What problem does this paper attempt to address?